44 results about "Receptor-mediated endocytosis" patented technology

The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration.

The invention belongs to the field of biomedicine and particularly discloses the application of gold nanocluster in preparation of a drug for treating tumors. Experimental study discovers that the gold nanocluster can enter cells by virtue of receptor-mediated endocytosis, form endosome and fuse with lysosome so as to deposit in the lysosome. Under light conditions, a photo chemical reaction is carried out on the surface of the gold nanocluster, production of reactive oxide species (ROS) is triggered, apoptosis is initiated, and the ROS can further attack cytoskeleton to cause cytoskeleton fracture and functional damage. The invention firstly proposes that the gold nanocluster can serve as a novel nano-drug to be used for treatment of tumors. As the nano-drug, the gold nanocluster is excellent in biocompatibility and high in safety. As an inert metal, the gold has excellent biocompatibility, and small interference on normal physiological activities of organisms/cells and low toxicity;the gold nanocluster has an effect of killing the tumors under specified conditions only, and is high in using safety.

The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed.

The invention provides an active targeting type amphipathic polypeptide nano-drug carrier and preparation and application thereof, and belongs to the technical field of biological medicines. According to an amphipathic polypeptide, an alkyl chain serves as the hydrophobic end, a polypeptide chain with active targeting functional and side chain modification fluorescent functional molecules serves as the hydrophilic end, and an anti-tumor drug is wrapped in a hydrophobic cavity of a micelle formed by self-assembling the amphipathic polypeptide. The nano-carrier can actively target tumor cells and enter the tumor cells through receptor-mediated endocytosis, the amphipathic polypeptide and phospholipid molecules have strong interaction, and the phagocytosis of a nano-drug by tumor cells is promoted. In the process, tracing can be conducted through fluorescent imaging of fluorescent functional molecules modified on the polypeptide chain, and the tumor imaging aim is realized. Finally, the anti-tumor drug is slowly released to kill tumor cells and restrain the growth of tumors. The amphipathic polypeptide nano-carrier is free of toxin, high in biocompatibility and remarkable in anti-tumor efficiency, and the tumor diagnosis and treatment can be integrated.

The present invention relates to a delivery carrier including liposomes or nanoparticles for targeting the cells expressed with somatostatin receptor, consisting of a plurality of liposomes that have one phospholipid bilayer coating, one hydrophilic core and a bioactive substance. The bioactive substance is packaged in the hydrophilic core, or embedded in the phospholipid bilayer, or electrically bound with liposomes as a complex, wherein the phospholipid bilayer coating is conjugated with a plurality of molecules in the outer surface. The molecules recognize the somatostatin receptor in the surface of the target cells and induce receptor-mediated endocytosis.

The invention discloses a cancer cell-targeting structural molecule and a use thereof. A molecule shown in the formula (I) reacts with a connection molecule containing a carboxyl structure and a maleimide group so that the cancer cell-targeting structural molecule is produced by a dehydration synthesis reaction of an amino group and a carboxyl group. The cancer cell-targeting structural molecule can be bonded with a sulfydryl (-SH)-modified nucleotide molecule, can be directly applied to a human body by blood vessel administration, can be specifically bonded with cancer cells expressing integrin family alpha v beta 3 acceptors or with new vessel endothelial cells in cancer tissue, can effectively penetrate a cell membrane by receptor-mediated endocytosis, and can convey the nucleotide molecule into cytoplasm. In the formula (I), n is in a range of 1-10.

The invention relates to a preparation method of an intelligent nanoparticle capable of specifically accelerating tumor cell apoptosis and monitoring the curative effect by itself. According to the intelligent nanoparticle, poly(D,L-lactide-co-glycolide)-polyethylene glycol, poly(D,L-lactide-co-glycolide)-polyetherimide and distearoyl phosphoethanolamine-polyethylene glycol-folic acid are adopted as a carrier and covered with hydrophobic anticancer drugs and caspase-3 substrate fluorescent peptide through a one-step self-assembling process. The nanoparticlle can specifically recognize tumor cells overexpressed by folate receptors, and enters lysosome through receptor-mediated endocytosis. By means of the proton sponge effect of polyetherimide, a lysosome membrane is through, escape of the drugs from the lysosome is promoted, tumor cell apoptosis is induced, the iconic caspase-3 of cell apoptosis is activated, the substrate fluorescent peptide is cut, fluorescent signals are generated and used for monitoring the curative effect in real time, precise treatment of tumor cells is achieved, and great tumor diagnosis and treatment application prospects are achieved.

The invention discloses a neutrophile granulocyte drug-loading preparation and applications of the neutrophile granulocyte drug-loading preparation. According to the neutrophile granulocyte drug-loading preparation, neutrophile granulocytes are taken as carriers, to-be-loaded drugs enter the carriers under the effect of receptor-mediated endocytosis, macropinocytosis or phagocytosis, and thus the neutrophile granulocyte drug-loading preparation is obtained; aiming at the defects in the existing targeting preparations, the neutrophile granulocyte drug-loading preparation has the advantages that rat neutrophile granulocytes and the drugs are co-incubated, so that the drug-loading cells are formed and then used for the in-vivo drug delivery, and finally, the targeting efficiency is improved.

The invention discloses a hyaluronic acid-g-folic acid amphiphilic polymer and application thereof. By a main chain namely hydrophilic hyaluronic acid and a side chain namely hydrophobic folic acid, efficient and stable loading of a micromolecular anticancer drug can be realized, and the blood circulation time of the drug is prolonged; high gathering amount at a tumor part is realized and reaches12.0%ID/g, and after reaching tumor tissues, a dual-targeted nano drug is closely combined with the tumor cell surface and effectively enters tumor cells under the action of receptor mediated endocytosis to realize quick release of the drug in the tumor cells, so that an efficient therapeutic effect is achieved. The polymer is high in biocompatibility and degradability and can be excreted conveniently; defects of low drug loading efficiency, small gathering amount at the tumor parts, low cell endocytosis efficiency, low release speed in cells and the like are overcome. In addition, a preparation method is simple, raw material sources are rich, and the nano drug is excellent in lyophilization redispersibility and beneficial to large-scale production and application.

The invention provides a medicine complex capable of enhancing antitumor immune response, which is a complex of Foxp3 siRNA-protamine-anti-CD25 antibody. Experiments show that the medicine can deliver the Foxp3 siRNA to a Treg cell in a target mode, enter the cell through receptor-mediated endocytosis, realize the gene silencing to Foxp3, and specifically inhibit] the function of the Treg, thereby raising the antitumor immune response capability for stimulating tumor antigens. The medicine can be widely applied to assisting the resistance of tumor.

The invention belongs to the technical field of drug transfer, and particularly relates to a target drug loaded micelle suitable for loading of hydrophobic chemical drugs. Amphipathic biodegradable materials (such as PCL-PEG ) and chemical drugs, which are safe to human bodies, are used to form stable nanometer crystallization micelles, so that the biological availability of drugs is improved, thecritical concentration of the micelles is reduced, and the in vitro long-acting cycle is realized; and tumor cells can be efficiently targeted, the chemical drugs enter the cells through receptor mediated endocytosis, and through self degradation, the drugs are released. The united target treatment of antibodies and the chemical drugs is performed on antibody antigen high-expression malignant tumours.

The present invention provides the modular design and assembly of novel targeting bio-conjugates, exclusively assembled by means of biotin-biotin binding element conjugation, comprising mono-biotinylated cell binding component, a tetrameric biotin-binding element, and mono-biotinylated payload for therapeutic and diagnostic purposes. In addition, there is provided a method of delivering the payload, such as therapeutic oligonucleotides, via mono-biotinylated targeting devices, such as antibodies or ligands, into eukaryotic cells by means of receptor-mediated endocytosis. The targeting bio-conjugates are suitable for use in the areas of medicine, pharmacy and biomedical research.

The invention discloses a metal-organic matter complex nanometer material as well as a preparation method and applications of the metal-organic matter complex nanometer material, and belongs to the technical field of preparation of antitumor medicines. The preparation method comprises the following steps: adding bovine serum albumin into an alkaline solution, simultaneously dropwise adding coppernitrate solution and 5- nitro-8-hydroxyquinoline solution, and carrying out reaction under the room temperature, so that the metal-organic matter complex nanometer material is obtained through productself-assembly. Through the simple and pollution-free preparation route, the prepared nanometer material has the advantages of good stability, long in-vivo circulation time, good targeting property and biological compatibility, small toxic and side effects, and the like. The provided nanometer material can be applied to tumor treatment as a nanometer medicine, and gathers in the tumor tissue through the EPR effect and the receptor-mediated endocytosis, so that the treatment effect of the metal-organic matter medicine for tumors is improved, and the systemic administration of the metal-organicmatter medicine can be realized.

The present invention describes new compounds that are useful for image-guided surgery and photodynamic therapy. In particular the compounds may be targeted to the nucleus or the mitochondria after compounds were delivered to diseased tissues such as cancer using a ligand that target receptor that express on the diseased tissue and followed by receptor mediated endocytosis and provide effective activity against cancer cells as well as other disorders. Methods and compositions for use of the same are described.